Company: SNY
Filing Date: 2025-10-29
Form Type: 424B5
Source: 0001193125-25-255563
Chunk: 73

Company: Sanofi
Filing Date: 2025-10-29
Form: 424B5
Chunk 73
---
7 |
| USE OF PROCEEDS                                           |     |      | 10 |
| DESCRIPTION OF DEBT SECURITIES WE MAY OFFER               |     |      | 11 |
| LEGAL OWNERSHIP                                           |     |      | 22 |
| CLEARANCE AND SETTLEMENT                                  |     |      | 24 |
| TAXATION OF DEBT SECURITIES                               |     |      | 28 |
| PLAN OF DISTRIBUTION                                      |     |      | 38 |
| VALIDITY OF SECURITIES                                    |     |      | 40 |
| EXPERTS                                                   |     |      | 40 |

ABOUT THIS PROSPECTUS This prospectus is part of a registration statement that Sanofi filed on April 4, 2024 with the SEC using the shelf registration process. Sanofi may sell the debt securities described in this prospectus in one or more offerings. This prospectus provides you with a general description of the debt securities that Sanofi may offer. Each time Sanofi sells debt securities, it will provide one or more prospectus supplements that will contain specific information about the terms of those securities and the offering to which it relates. The prospectus supplement(s) may also add, update or change information contained, or incorporated by reference, in this prospectus. You should read both this prospectus and any applicable prospectus supplement(s) together with the additional information described under the heading “Where You Can Find More Information” and “Incorporation by Reference” prior to purchasing any of the debt securities offered by this prospectus. Unless otherwise indicated, information and statistics presented herein relating to Sanofi’s ranking information and market share relative to its competitors are based on its own research and/or various publicly available sources, which may be adjusted as further described under the heading “Presentation of financial and other information” in our Annual Report on Form 20-Ffor the financial year ended December 31, 2023 (the “2023 Form 20-F”).Data relative to market share and ranking information presented herein or in documents incorporated by reference herein for our vaccines business is based on internal estimates unless stated otherwise. As used herein, the terms “Sanofi,” the “Company,” the “Group,” “we,” “our,” or “us,” unless the context otherwise requires, refer to Sanofi S.A. (as defined hereinafter) and its consolidated subsidiaries, and “Sanofi S.A.” refers to the parent company, a French société anonyme(limited liability company), without